Paul Hastings
2017 - OncoMed Pharmaceuticals
In 2017, Paul Hastings earned a total compensation of $2.6M as Former Chairman, Chief Executive Officer & President at OncoMed Pharmaceuticals, a 175% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $60,624 |
|---|---|
| Option Awards | $1,857,110 |
| Salary | $551,127 |
| Stock Awards | $169,650 |
| Total | $2,638,511 |
Hastings received $1.9M in option awards, accounting for 70% of the total pay in 2017.
Hastings also received $60.6K in non-equity incentive plan, $551.1K in salary and $169.7K in stock awards.
Rankings
In 2017, Paul Hastings' compensation ranked 4,210th out of 14,666 executives tracked by ExecPay. In other words, Hastings earned more than 71.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,210 out of 14,666 | 71st |
Division Manufacturing | 1,474 out of 5,768 | 74th |
Major group Chemicals And Allied Products | 423 out of 2,074 | 80th |
Industry group Drugs | 324 out of 1,730 | 81st |
Industry Pharmaceutical Preparations | 257 out of 1,329 | 81st |
Source: SEC filing on April 27, 2018.
Hastings' colleagues
We found four more compensation records of executives who worked with Paul Hastings at OncoMed Pharmaceuticals in 2017.